These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

151 related items for PubMed ID: 14742213

  • 1. Determination of ddATP levels in human immunodeficiency virus-infected patients treated with dideoxyinosine.
    Le Saint C, Terreux R, Duval D, Durant J, Ettesse H, Dellamonica P, Guedj R, Vincent JP, Cupo A.
    Antimicrob Agents Chemother; 2004 Feb; 48(2):589-95. PubMed ID: 14742213
    [Abstract] [Full Text] [Related]

  • 2. Intracellular nucleotide levels during coadministration of tenofovir disoproxil fumarate and didanosine in HIV-1-infected patients.
    Hawkins T, Veikley W, Durand-Gasselin L, Babusis D, Reddy YS, Flaherty JF, Ray AS.
    Antimicrob Agents Chemother; 2011 Apr; 55(4):1549-55. PubMed ID: 21282432
    [Abstract] [Full Text] [Related]

  • 3. Pharmacodynamic studies (PD) of didanosine (ddI) alone and in combination with azidothymidine (AZT) in human T-cells; a stochastic biochemical approach to antiretroviral nucleoside drug combination in inhibiting HIV-reverse transcriptase (RT).
    Periclou AP, Nandy P, Avramis VI.
    In Vivo; 2000 Apr; 14(3):377-88. PubMed ID: 10904870
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Monitoring of didanosine and stavudine intracellular trisphosphorylated anabolite concentrations in HIV-infected patients.
    Becher F, Landman R, Mboup S, Kane CN, Canestri A, Liegeois F, Vray M, Prevot MH, Leleu G, Benech H.
    AIDS; 2004 Jan 23; 18(2):181-7. PubMed ID: 15075534
    [Abstract] [Full Text] [Related]

  • 7. Interpretation of the roles of adenylosuccinate lyase and of AMP deaminase in the anti-HIV activity of 2',3'-dideoxyadenosine and 2',3'-dideoxyinosine.
    Nair V, Sells TB.
    Biochim Biophys Acta; 1992 Feb 26; 1119(2):201-4. PubMed ID: 1540653
    [Abstract] [Full Text] [Related]

  • 8. Effect of hydroxyurea and dideoxyinosine on intracellular 3'-deoxyadenosine-5'-triphosphate concentrations in HIV-infected patients.
    Bakshi RP, Hamzeh F, Frank I, Eron JJ, Bosch RJ, Rosenkranz SL, Cramer YS, Ussery M, Flexner C.
    AIDS Res Hum Retroviruses; 2007 Nov 26; 23(11):1360-5. PubMed ID: 18184078
    [Abstract] [Full Text] [Related]

  • 9. Enzymatic phosphorylation and pyrophosphorylation of 2',3'-dideoxyadenosine-5'-monophosphate, a key metabolite in the pathway for activation of the anti-HIV (human immunodeficiency virus) agent 2',3'-dideoxyinosine.
    Navé JF, Eschbach A, Wolff-Kugel D, Halazy S, Balzarini J.
    Biochem Pharmacol; 1994 Sep 15; 48(6):1105-12. PubMed ID: 7945403
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Anomalous accumulation and decay of 2',3'-dideoxyadenosine-5'-triphosphate in human T-cell cultures exposed to the anti-HIV drug 2',3'-dideoxyinosine.
    Ahluwalia G, Cooney DA, Hartman NR, Mitsuya H, Yarchoan R, Fridland A, Broder S, Johns DG.
    Drug Metab Dispos; 1993 Sep 15; 21(2):369-76. PubMed ID: 8097711
    [Abstract] [Full Text] [Related]

  • 16. A phase-I study of the safety, pharmacokinetics, and antiviral activity of combination didanosine and ribavirin in patients with HIV-1 disease. AIDS Clinical Trials Group 231 Protocol Team.
    Japour AJ, Lertora JJ, Meehan PM, Erice A, Connor JD, Griffith BP, Clax PA, Holden-Wiltse J, Hussey S, Walesky M, Cooney E, Pollard R, Timpone J, McLaren C, Johanneson N, Wood K, Booth D, Bassiakos Y, Crumpacker CS.
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Nov 01; 13(3):235-46. PubMed ID: 8898668
    [Abstract] [Full Text] [Related]

  • 17. Phase I dose-escalation pharmacokinetics of AZT-P-ddI (IVX-E-59) in patients with human immunodeficiency virus.
    Zhou XJ, Squires K, Pan-Zhou XR, Bernhard S, Agrofoglio L, Kirk M, Duchin KL, Sommadossi JP.
    J Clin Pharmacol; 1997 Mar 01; 37(3):201-13. PubMed ID: 9089422
    [Abstract] [Full Text] [Related]

  • 18. Role of altered metabolism in dideoxynucleoside pharmacokinetics. Studies of 2'-beta-fluoro-2',3'-dideoxyinosine and 2'-beta-fluoro-2',3'-dideoxyadenosine in rats.
    Singhal D, Morgan ME, Anderson BD.
    Drug Metab Dispos; 1996 Oct 01; 24(10):1155-61. PubMed ID: 8894519
    [Abstract] [Full Text] [Related]

  • 19. Pharmacokinetics of didanosine and drug resistance mutations in infants exposed to zidovudine during gestation or postnatally and treated with didanosine or zidovudine in the first three months of life.
    Kovacs A, Cowles MK, Britto P, Capparelli E, Fowler MG, Moye J, McIntosh K, Rathore MH, Pitt J, Husson RN.
    Pediatr Infect Dis J; 2005 Jun 01; 24(6):503-9. PubMed ID: 15933559
    [Abstract] [Full Text] [Related]

  • 20. Pharmacokinetics of oral ganciclovir alone and in combination with zidovudine, didanosine, and probenecid in HIV-infected subjects.
    Cimoch PJ, Lavelle J, Pollard R, Griffy KG, Wong R, Tarnowski TL, Casserella S, Jung D.
    J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Mar 01; 17(3):227-34. PubMed ID: 9495222
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.